Literature DB >> 18223500

Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease.

Matthew R Donaldson1, Linda S Book, Kristin M Leiferman, John J Zone, Susan L Neuhausen.   

Abstract

GOALS: Our objective was to determine whether high serologic IgA tissue transglutaminase antibodies (TTGA) are exclusively associated with celiac disease (CD).
BACKGROUND: IgA TTGA are found in the serum of most individuals with CD. This serologic marker is used to screen individuals with suspected CD for duodenal biopsy, the gold standard of CD diagnosis. Data suggest strongly positive IgA TTGA >or= 100 units are highly specific for CD histopathology in pediatric patients and may be sufficient for diagnosis. STUDY: Records of adult and pediatric subjects in the celiac study at the University of Utah and University of California Irvine were reviewed for strongly positive TTGA. Pathology reports from duodenal biopsies of subjects with IgA TTGA >or= 100 units were graded as 0 to 3 by modified Marsh criteria.
RESULTS: From a pool of 1882 subjects with IgA TTGA assayed, 208 had IgA TTGA >or= 100 units. Seventy-six of these, including 28 children and 48 adults, also had duodenal biopsies. Villous atrophy (Marsh 3 histopathology) was found on biopsy in 73 (96%) of these subjects. The remaining 3 subjects had intermediate Marsh histology. One (Marsh 1) had a complete serologic response to a gluten-free diet and 2 had Marsh 2 lesions and positive endomysium, making early CD most likely.
CONCLUSIONS: IgA TTGA >or= 100 units occur almost exclusively in the setting of Marsh 3 duodenal histopathology in adults and children. Rare cases without villous atrophy were marked by intermediate Marsh changes suggestive of early CD. IgA TTGA >or= 100 arbitrary units indicate duodenal changes consistent with CD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223500     DOI: 10.1097/MCG.0b013e31802e70b1

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  37 in total

1.  Application of the Biopsy-Sparing ESPGHAN Guidelines for Celiac Disease Diagnosis in Adults: A Real-Life Study.

Authors:  Konstantinos Efthymakis; Mariaelena Serio; Angelo Milano; Francesco Laterza; Antonella Bonitatibus; Marta Di Nicola; Matteo Neri
Journal:  Dig Dis Sci       Date:  2017-07-17       Impact factor: 3.199

2.  Can High Titres of Anti Tissue Transglutaminase Antibodies Reduce the Need for Intestinal Biopsy for Diagnosis of Celiac Disease?

Authors:  Ekta Bansal; Navpreet Kaur; Naveen Mittal
Journal:  Indian J Clin Biochem       Date:  2017-09-13

3.  Intestinal titres of anti-tissue transglutaminase 2 antibodies correlate positively with mucosal damage degree and inversely with gluten-free diet duration in coeliac disease.

Authors:  A Tosco; R Auricchio; R Aitoro; D Ponticelli; M Primario; E Miele; V Rotondi Aufiero; V Discepolo; L Greco; R Troncone; M Maglio
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 4.  Challenges in the Standardization of Autoantibody Testing: a Comprehensive Review.

Authors:  Renato Tozzoli; Danilo Villalta; Nicola Bizzaro
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

5.  Prevalence and Clinical Features of Celiac Disease in Healthy School-Aged Children.

Authors:  Omer Faruk Beser; Emine Gulluelli; Fugen Cullu Cokugras; Tulay Erkan; Tufan Kutlu; Rasit Vural Yagci; Firuze Erbek Alp; Gulten Ercal; Nuray Kepil; Mine Kucur
Journal:  Dig Dis Sci       Date:  2018-10-12       Impact factor: 3.199

6.  Identification of Pediatric Patients With Celiac Disease Based on Serology and a Classification and Regression Tree Analysis.

Authors:  Anna Ermarth; Matthew Bryce; Stephanie Woodward; Gregory Stoddard; Linda Book; M Kyle Jensen
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-12       Impact factor: 11.382

7.  High-titre circulating tissue transglutaminase-2 antibodies predict small bowel villous atrophy, but decision cut-off limits must be locally validated.

Authors:  L Beltran; M Koenig; W Egner; M Howard; A Butt; M R Austin; D Patel; R R Sanderson; S Goubet; F Saleh; J Lavender; E Stainer; M D Tarzi
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

8.  Performance of serology assays for diagnosing celiac disease in a clinical setting.

Authors:  Miriam Parizade; Yoram Bujanover; Batya Weiss; Vered Nachmias; Bracha Shainberg
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

9.  Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines.

Authors:  Jiri Nevoral; Radana Kotalova; Ondrej Hradsky; Vera Valtrova; Kristyna Zarubova; Jan Lastovicka; Eva Neubertova; Marketa Trnkova; Jiri Bronsky
Journal:  Eur J Pediatr       Date:  2013-11-15       Impact factor: 3.183

10.  Tissue transglutaminase levels above 100 U/mL and celiac disease: a prospective study.

Authors:  Amani Mubarak; Victorien M Wolters; Frits H J Gmelig-Meyling; Fiebo J W Ten Kate; Roderick H J Houwen
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.